CTNNB1, catenin beta 1, 1499

N. diseases: 1368; N. variants: 68
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Silencing LGR6 Attenuates Stemness and Chemoresistance via Inhibiting Wnt/β-Catenin Signaling in Ovarian Cancer. 31193124 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 AlteredExpression disease BEFREE Further, the expression of SOX9, β-catenin, and c-Myc in OC tissues was upregulated and inversely correlated with miR-34c expression, indicating that rescuing miR-34c expression, thus to inhibit SOX9, β-catenin, and c-Myc expression presents a promising strategy of reducing the chemoresistance of the OC cell to DDP. 30537410 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating β-catenin. 31653698 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Our work also provides a proper understanding on the regulation of Wnt/β-catenin pathway in ovarian cancer. 30572097 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) promotes the EMT of serous ovarian cancer by activating the hexosamine biosynthetic pathway to increase the nuclear location of β-catenin. 31685298 2019
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.900 Biomarker disease BEFREE Our work also provides a proper understanding on the regulation of Wnt/β-catenin pathway in ovarian cancer. 30572097 2019
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.900 AlteredExpression disease BEFREE Further, the expression of SOX9, β-catenin, and c-Myc in OC tissues was upregulated and inversely correlated with miR-34c expression, indicating that rescuing miR-34c expression, thus to inhibit SOX9, β-catenin, and c-Myc expression presents a promising strategy of reducing the chemoresistance of the OC cell to DDP. 30537410 2019
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.900 Biomarker disease BEFREE Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating β-catenin. 31653698 2019
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.900 Biomarker disease BEFREE Silencing LGR6 Attenuates Stemness and Chemoresistance via Inhibiting Wnt/β-Catenin Signaling in Ovarian Cancer. 31193124 2019
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.900 Biomarker disease BEFREE Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) promotes the EMT of serous ovarian cancer by activating the hexosamine biosynthetic pathway to increase the nuclear location of β-catenin. 31685298 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE These results suggested that miR-214 may serve as a tumor suppressor of ovarian cancer by targeting the β-catenin pathway. 29486472 2018
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 AlteredExpression disease BEFREE Nucleus and/or cytoplasma of β-catenin expression might be associated with tumor progression and could be a possible potential predictive factor of poor prognosis in OC patients. 30103006 2018
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.900 Biomarker disease BEFREE These results suggested that miR-214 may serve as a tumor suppressor of ovarian cancer by targeting the β-catenin pathway. 29486472 2018
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.900 AlteredExpression disease BEFREE Nucleus and/or cytoplasma of β-catenin expression might be associated with tumor progression and could be a possible potential predictive factor of poor prognosis in OC patients. 30103006 2018
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Our work highlights the therapeutic value of inhibiting Wnt/β-catenin in ovarian cancer. 28090074 2017
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE These results uncover β-catenin as a critical factor in promoting ovarian cancer aggressiveness and a new mechanism linking between β-catenin and miRNA downregulation underlying this process. 28650464 2017
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Taken together, this study showed that Annexin A2 inhibition suppresses proliferation and invasion in ovarian cancer via β-catenin/EMT, proposing the potential role of Annexin A2 in the prevention and treatment of ovarian cancer. 28440436 2017
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.900 Biomarker disease BEFREE Our work highlights the therapeutic value of inhibiting Wnt/β-catenin in ovarian cancer. 28090074 2017
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.900 Biomarker disease BEFREE Taken together, this study showed that Annexin A2 inhibition suppresses proliferation and invasion in ovarian cancer via β-catenin/EMT, proposing the potential role of Annexin A2 in the prevention and treatment of ovarian cancer. 28440436 2017
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.900 Biomarker disease BEFREE These results uncover β-catenin as a critical factor in promoting ovarian cancer aggressiveness and a new mechanism linking between β-catenin and miRNA downregulation underlying this process. 28650464 2017
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Our study identifies activated Wnt signalling to be a marker for precursor lesions of OC and successfully develops a mouse model that mimics the earliest events in pathogenesis of OC by constitutively activating βcatenin. 27588493 2016
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/β-catenin pathway in human ovarian cancer. 26341496 2016
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 AlteredExpression disease BEFREE JRK is a positive regulator of β-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer. 26455321 2016
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.900 AlteredExpression disease BEFREE Importantly, JRK expression was aberrantly elevated in 21% of colorectal cancers, 15% of breast and ovarian cancers and was associated with increased expression of β-catenin target genes and increased cell proliferation. 26455321 2016
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.900 Biomarker disease BEFREE Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/β-catenin pathway in human ovarian cancer. 26341496 2016